The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company's total liabilities are $124.31 B. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2023-12-31 | $124.31 B | 2.3% |
2022-12-31 | $121.51 B | -7.3% |
2021-12-31 | $131.09 B | -4.64% |
2020-12-31 | $137.46 B | 41.3% |
2019-12-31 | $97.28 B | 43.5% |
2018-12-31 | $67.79 B | 3.21% |
2017-12-31 | $65.68 B | 6.88% |
2016-12-31 | $61.46 B | 25.17% |
2015-12-31 | $49.10 B | 90.54% |
2014-12-31 | $25.77 B | 4.31% |
2013-12-31 | $24.70 B | 4.49% |
2012-12-31 | $23.64 B | 211.57% |
2011-12-31 | $7.58 B | 39.72% |
2010-12-31 | $5.43 B |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $137.21 B | 10.38% | ๐บ๐ธ USA |
Eli Lilly LLY | $53.14 B | -57.25% | ๐บ๐ธ USA |
Amgen AMGN | $90.92 B | -26.86% | ๐บ๐ธ USA |
Biogen BIIB | $12.04 B | -90.31% | ๐บ๐ธ USA |
Gilead Sciences GILD | $39.37 B | -68.33% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $65.67 B | -47.17% | ๐บ๐ธ USA |
AstraZeneca AZN | $61.95 B | -50.16% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $58.82 B | -52.68% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $1.01 B | -99.18% | ๐บ๐ธ USA |